VeonGen Reports FDA Alignment on VG801 Phase 3 Study Design
VeonGen says it aligned with the FDA on the pivotal Phase 3 study design and CMC strategy for VG801, a treatment for Stargardt disease.
VeonGen says it aligned with the FDA on the pivotal Phase 3 study design and CMC strategy for VG801, a treatment for Stargardt disease.